STOCK TITAN
  1. Home
  2. Sec-filings
  3. KNSA
  4. [Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity

[Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4
Insider Tessari Eben
Role CHIEF OPERATING OFFICER
Sold 138,614 shs ($4.60M)
Type Security Shares Price Value
Exercise Share Option 38,928 $0.00 --
Exercise Share Option 30,444 $0.00 --
Exercise Share Option 32,710 $0.00 --
Exercise Share Option 25,896 $0.00 --
Exercise Share Option 10,636 $0.00 --
Exercise Class A Ordinary Share 38,928 $10.36 $403K
Exercise Class A Ordinary Share 30,444 $12.97 $395K
Exercise Class A Ordinary Share 32,710 $11.10 $363K
Exercise Class A Ordinary Share 25,896 $11.97 $310K
Exercise Class A Ordinary Share 10,636 $10.76 $114K
Sale Class A Ordinary Share 138,064 $33.20 $4.58M
Sale Class A Ordinary Share 550 $33.90 $19K
Grant/Award Class A Ordinary Share 752 $15.63 $12K
Holdings After Transaction: Share Option — 0 shares (Direct); Class A Ordinary Share — 88,843 shares (Direct)
Footnotes (1)
  1. The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2025 to July 15, 2025. The acquisition of these shares was exempt pursuant to Rule 16B-3(e). This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $32.83 and $33.82. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $33.83 and $33.98. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. The option is fully vested and exercisable. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2023.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tessari Eben
(Last) (First) (Middle)
23 OLD BOND STREET, THIRD FLOOR
(Street)
LONDON X0 W1S 4PZ
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF OPERATING OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
07/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Ordinary Share 07/15/2025 A(1) 752 A $15.63 49,915 D
Class A Ordinary Share 08/05/2025 M(2) 38,928 A $10.36 88,843 D
Class A Ordinary Share 08/05/2025 M(2) 30,444 A $12.97 119,287 D
Class A Ordinary Share 08/05/2025 M(2) 32,710 A $11.1 151,997 D
Class A Ordinary Share 08/05/2025 M(2) 25,896 A $11.97 177,893 D
Class A Ordinary Share 08/05/2025 M(2) 10,636 A $10.76 188,529 D
Class A Ordinary Share 08/05/2025 S(2) 138,064 D $33.2(3) 50,465 D
Class A Ordinary Share 08/05/2025 S(2) 550 D $33.9(4) 49,915 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Share Option $10.36 08/05/2025 M(2) 38,928 (5) 02/29/2028 Class A Ordinary Share 38,928 $0 0 D
Share Option $12.97 08/05/2025 M(2) 30,444 (6) 09/01/2031 Class A Ordinary Share 30,444 $0 16,694 D
Share Option $11.1 08/05/2025 M(2) 32,710 (7) 04/06/2032 Class A Ordinary Share 32,710 $0 32,710 D
Share Option $11.97 08/05/2025 M(2) 25,896 (8) 08/31/2032 Class A Ordinary Share 25,896 $0 39,524 D
Share Option $10.76 08/05/2025 M(2) 10,636 (9) 03/31/2033 Class A Ordinary Share 10,636 $0 31,908 D
Explanation of Responses:
1. The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2025 to July 15, 2025. The acquisition of these shares was exempt pursuant to Rule 16B-3(e).
2. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.
3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $32.83 and $33.82. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
4. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $33.83 and $33.98. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
5. The option is fully vested and exercisable.
6. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021.
7. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022.
8. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022.
9. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2023.
/s/ Madelyn Zeylikman, Attorney-in-Fact 08/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR